Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Boguszewski MCS, CL Boguszewski, Wassim Chemaitilly, Cohen LE, Judith Gebauer, Claire Higham, Andrew R. Hoffman, Michel Polak, Yuen KCJ, Nathalie Alos, Zoltan Antal, M Bidlingmaier, Biller BMK, Georg Brabant, Choong CSY, Stefano Cianfarani, Clayton Pe, R. Coutant, Cardoso-Demartini AA, Alberto Fernández, Adda Grimberg, Kolbeinn Guðmundsson, Jaime Guevara‐Aguirre, Ho KKY, Reiko Horikawa, Isidori AM, Jørgensen JOL, Peter Kamenický, Niki Karavitaki, Kopchick Jj, Maya Lodish, Luo Xu, McCormack AI, Lillian R. Meacham, Шломо Мелмед, Sogol Mostoufi‐ Moab, Hermann L. Müller, Neggers SJCMM, MH Aguiar Oliveira, Keiichi Ozono, P.A. Low PA, Vera Popović, Sally Radovick, Lars Sävendahl, Philippe Touraine, Hanneke M. van Santen, G Johannsson
Abstract
Brief Summary: An international panel of experts produced this consensus statement after critical review of the existing evidence on the safety of GH replacement in cancer and intracranial tumour survivors and in patients with increased cancer risk.